One missed rule can cost you your license.

There is a free tier, two subscription levels, and one-time reports. Free: subscribe with your email for the weekly Med Spa Radar Brief and see what changed across everything we watch — all 50 state legislatures, the FDA, and the Federal Register. Solo-State ($29/month founding, then $39) watches a single state in real time with the full what-to-do on every change in it, plus federal and nationally-significant alerts. All-Access ($99/month founding for the first 50 practices, then $149) covers every state we monitor and adds your personalized, printable Compliance Brief, the GLP-1 Compounding Intelligence view, and the compliance checklists. Prefer to buy once? One-time packs need no subscription — a $49 State Compliance Snapshot (credited toward a subscription within 30 days) and a $97 Peptide & GLP-1 Status Pack. Monitoring, not legal advice.

You can buy once — no subscription required. The $49 State Compliance Snapshot is an instant, source-linked report of every published med-spa and injectable change for your state, with the federal record included; if you subscribe within 30 days, the $49 is credited toward it. The $97 Peptide & GLP-1 Status Pack is the current federal standing of every tracked substance plus your state's overlay and change history, re-purchasable as standings move. All-Access members get these packs included for their states. Monitoring, not legal advice.

Med Spa Radar is purpose-built early-warning monitoring — not a membership directory, a one-time consult, or a keyword alert. It reads all 50 state legislatures plus the FDA and Federal Register every day, scores each change for its impact on aesthetic practices, has a human review it, and tells you in plain language what changed and what to do, linked to the primary source. A trade association or an attorney helps you after you already know there is a problem; Google Alerts surface noise, not bills and FDA actions parsed for med-spa relevance. Med Spa Radar is the layer that tells you first — so you fix things proactively instead of hearing about them from a board complaint. It complements your counsel; it does not replace it.

It depends on two things that change frequently: whether the drug is on the FDA shortage list, and your state’s rules. Under federal law (sections 503A and 503B), a compounder generally may not make a copy of a commercially available drug — being on the FDA shortage list has been the main exception that allowed compounded semaglutide and tirzepatide. When the FDA declared those shortages resolved, the basis for compounded versions narrowed sharply. Med Spa Radar tracks FDA shortage status and state action daily so you know when it changes. This is regulatory monitoring, not legal advice.

It depends on whether the peptide is on the FDA’s 503A Bulks List — and as of the July 2026 Pharmacy Compounding Advisory Committee (PCAC) meetings, none of the headline peptides are. PCAC recommended further review of BPC-157, KPV, TB-500, and MOTS-c, but a recommendation is not a legal status change: FDA is not bound by it, and actually permitting 503A compounding requires notice-and-comment rulemaking, commonly 8–12 months. So these remain not compoundable under 503A today. FDA has separately scheduled a further PCAC meeting by the end of February 2027 for five more peptides (GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF). We track each substance’s current standing, with its government source and date, on the Med Spa Radar substance tracker. This is regulatory monitoring, not legal advice.

The Med Spa Radar substance tracker lists every peptide and GLP-1 we monitor with its current federal standing — 503A Bulks List status, PCAC review history, and any state overlay — each linked to the government document it came from and dated. Where an outcome has so far only been reported by trade press (as with the July 2026 PCAC votes), it is marked "reported" until FDA’s primary record posts, so the tracker never overstates its own sourcing. It is free to view. Monitoring, not legal advice.

The FDA drug shortage list is a primary factor in whether compounding pharmacies (503A) and outsourcing facilities (503B) may prepare copies of a drug such as semaglutide or tirzepatide. When a GLP-1 comes off the shortage list, that basis for compounding generally ends — often after a short wind-down period. We monitor the list and alert you as soon as a GLP-1’s status changes.

503A pharmacies compound patient-specific prescriptions; 503B outsourcing facilities make larger batches under tighter FDA oversight and cGMP standards. For GLP-1s, both pathways generally hinge on FDA shortage status. The distinction drives which compounded products a med spa can legally source and from whom — so a change to either pathway can affect your supply overnight.

In most states, yes. Aesthetic procedures like injectables and lasers are considered the practice of medicine, which typically requires a physician owner, a medical director, or a supervising/delegating physician relationship. The specifics — ownership rules, delegation, chart review, and how often the physician must be involved — vary by state and change through legislation, which is exactly what Med Spa Radar tracks.

A good-faith exam (GFE) is a clinical evaluation required before a patient is treated — for example before Botox or filler — to establish a valid provider-patient relationship and a treatment order. States increasingly regulate who may perform the GFE and whether it can be done over telehealth. New GFE rules are one of the most common scope-of-practice changes we surface.

It varies widely by state. Some states grant nurse practitioners broad independent authority; others require a delegating or supervising physician, an established good-faith exam, or physician availability. Because these scope-of-practice rules change through state legislation and licensing-board action, the safe answer is state-specific — and it moves. Med Spa Radar monitors all 50 states and DC for exactly these changes.

The practical challenge is awareness: rules change through hundreds of state bills plus FDA and Federal Register activity every session, and a single missed change can put a license or the business at risk. Med Spa Radar monitors all of those sources daily, scores each change for impact, and tells you in plain language what changed and what to do — so compliance starts with knowing first.

We scan all 50 state legislatures plus Washington, DC via LegiScan daily, plus federal activity from the U.S. Federal Register and the FDA — including the FDA drug-shortage database, the key signal for GLP-1 compounding legality. That is the monitoring scope; not every state has had a med-spa-relevant change yet, so you see the states that have (federal alerts apply everywhere). Every alert links directly to its primary source so you can verify it in one click.

Sources are scanned daily, and material changes are reviewed and published promptly to your feed and the weekly Med Spa Radar Brief. Because every alert is human-reviewed before publishing, you get speed without false alarms — a wrong compliance alert is worse than none.

No. Med Spa Radar is regulatory monitoring, not legal, medical, or compliance advice. We surface relevant changes early and link you to the primary source so you and your counsel can act on them. Always verify against the primary source and consult qualified counsel before making compliance decisions.

Med-spa owners, injectors, nurse practitioners, medical directors, and practice managers — anyone who offers GLP-1 weight-loss programs, injectables, or other aesthetic services and cannot afford to miss a scope-of-practice or compounding change that affects their license or their business.